5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.01▲ | 1.01▼ | 1.01▼ | 1.02▲ | 1.12▼ |
MA10 | 1.01▼ | 1.02▼ | 1.02▼ | 1.10▼ | 1.17▼ |
MA20 | 1.02▼ | 1.02▼ | 1.02▼ | 1.15▼ | 1.11▼ |
MA50 | 1.02▼ | 1.01▼ | 1.06▼ | 1.17▼ | 0.85▲ |
MA100 | 1.01▲ | 1.09▼ | 1.14▼ | 1.09▼ | 0.55▲ |
MA200 | 1.06▼ | 1.14▼ | 1.21▼ | 0.95▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.001▼ | -0.002▼ | 0.002▲ | -0.022▼ | -0.031▼ |
RSI | 43.565▼ | 45.809▼ | 39.505▼ | 38.345▼ | 48.844▼ |
STOCH | 20.833 | 13.056▼ | 31.521 | 19.870▼ | 31.252 |
WILL %R | -75.000 | -87.500▼ | -56.911 | -81.081▼ | -88.525▼ |
CCI | -26.667 | -63.415 | -75.339 | -81.715 | -94.659 |
Tuesday, August 19, 2025 04:15 AM
Castellum's (CTM) newly formed product subsidiary, Castellum Advanced Technology Products, has entered into a reseller agreement with Tradewinds Networks to resell their products to Castellum's ...
|
Thursday, August 14, 2025 03:59 AM
Castellum, Inc. Announces Aggregate Warrant Exercises Raising Additional Proceeds of Approximately $4.5 Million ...
|
Monday, July 21, 2025 07:10 AM
CTM-N2D is an innovative therapy using donor-derived gamma delta T cells targeting cancer-associated antigens for treating various malignancies. When will dose level 2 of the ANGELICA Trial start?
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
25/08/25 | 1.05 | 1.05 | 1.00 | 1.02 | 1,566,508 |
22/08/25 | 1.00 | 1.05 | 0.98 | 1.03 | 1,219,318 |
21/08/25 | 1.00 | 1.03 | 1.00 | 1.02 | 1,062,798 |
20/08/25 | 1.01 | 1.025 | 0.95 | 1.01 | 2,618,600 |
19/08/25 | 1.09 | 1.09 | 0.983 | 1.02 | 3,329,100 |
18/08/25 | 1.16 | 1.17 | 1.01 | 1.08 | 5,910,500 |
15/08/25 | 1.20 | 1.219 | 1.15 | 1.15 | 2,129,300 |
14/08/25 | 1.22 | 1.2484 | 1.18 | 1.21 | 2,039,987 |
13/08/25 | 1.20 | 1.25 | 1.20 | 1.25 | 2,572,400 |
12/08/25 | 1.22 | 1.24 | 1.16 | 1.19 | 2,881,100 |
|
|
||||
|
|
||||
|
|